Detalhe da pesquisa
1.
Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate.
Pharm Res
; 40(12): 3001-3010, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37821768
2.
Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.
Adv Exp Med Biol
; 1390: 255-275, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36107324
3.
The intravenous to oral switch of taxanes: strategies and current clinical developments.
Future Oncol
; 17(11): 1379-1399, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33356545
4.
A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
Int J Cancer
; 147(4): 1143-1151, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31875956
5.
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
BMC Cancer
; 20(1): 884, 2020 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32928177
6.
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer.
Future Oncol
; 16(19): 1371-1384, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469606
7.
Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer.
J Urol
; 201(3): 478-485, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30321552
8.
Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study.
Pharm Res
; 36(12): 181, 2019 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31732882
9.
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Lancet Oncol
; 18(4): 473-485, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28283282
10.
Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.
Prostate
; 76(1): 32-40, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26390914
11.
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Oncology
; 91(5): 267-273, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27544669
12.
Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
World J Urol
; 34(2): 157-62, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26184106
13.
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 15(7): 700-12, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24831977
14.
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Cancer
; 120(7): 968-75, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24382803
15.
Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.
BJU Int
; 114(1): 67-74, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24053889
16.
It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective.
Cancers (Basel)
; 16(2)2024 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38254784
17.
Agent-based modeling of the prostate tumor microenvironment uncovers spatial tumor growth constraints and immunomodulatory properties.
NPJ Syst Biol Appl
; 10(1): 20, 2024 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38383542
18.
Current Routine Testosterone Immunoassays Are Unsuitable for Lowering the General Castration Cutoff Recommendation to <0.7 nmol/l (20 ng/dl).
Eur Urol Open Sci
; 48: 98-100, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36654783
19.
Serum testosterone measured by liquid chromatography-tandem mass spectrometry is an independent predictor of response to castration in metastatic hormone-sensitive prostate cancer.
Clin Chim Acta
; 539: 34-40, 2023 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36460134
20.
Predictive value of low testosterone concentrations during and prior to enzalutamide treatment in metastatic castration-resistant prostate cancer.
Urol Oncol
; 41(2): 104.e11-104.e17, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36379811